Gujarat Themis Biosyn Ltd

Guj. Themis Bio. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Gujarat Themis Biosyn Ltd

₹ 433 -3.31%
18 Nov 4:01 p.m.
gtbl.in BSE: 506879 NSE: GUJTHEM
About

Incorporated in 1981, Gujarat Themis Biosyn
Ltd manufactures and sells finished Active Pharmaceutical Ingredients products by fermentation process[1]

Key Points

Business Overview[1][2]
Company manufactures pharmaceuticals and medicinal chemicals. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary). GTBL entered into Technical & Financial collaboration with Yuhan Corporation, South Korea, and became India’s first Company to start commercial production of the Anti-tuberculosis drug Rifampicin.

Website BSE NSE
  • Market Cap ₹ 4,711 Cr.
  • Current Price ₹ 433
  • High / Low ₹ 479 / 192
  • Stock P/E 97.6
  • Book Value ₹ 24.3
  • Dividend Yield 0.15 %
  • ROCE 27.3 %
  • ROE 21.7 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 31.5%
  • Company's working capital requirements have reduced from 62.3 days to 45.6 days

Cons

  • Stock is trading at 17.8 times its book value
  • Company might be capitalizing the interest cost
  • Debtor days have increased from 59.2 to 75.6 days.
  • Promoter holding has decreased over last 3 years: -4.13%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
48 28 28 50 40 39 42 39 35 40 38 36 42
23 16 13 26 23 21 21 20 19 21 22 22 21
Operating Profit 24 12 14 24 17 18 21 19 15 19 16 14 21
OPM % 51% 43% 52% 47% 42% 46% 50% 48% 44% 48% 42% 39% 49%
1 2 2 1 1 1 1 1 0 0 1 0 1
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 1 1 1 1 1 1 1 1 1 2 1 2 3
Profit before tax 25 13 16 24 17 18 21 18 14 17 16 12 19
Tax % 26% 26% 25% 26% 26% 26% 24% 26% 26% 25% 25% 25% 24%
19 10 12 18 13 13 16 13 11 13 12 9 14
EPS in Rs 1.72 0.90 1.07 1.63 1.15 1.19 1.46 1.21 0.97 1.19 1.10 0.83 1.31
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
30 31 33 36 39 41 85 91 115 148 170 151 155
24 25 27 30 33 34 53 50 57 75 91 81 86
Operating Profit 6 7 6 6 6 7 32 40 58 74 79 70 70
OPM % 21% 21% 19% 17% 16% 18% 37% 45% 51% 50% 46% 46% 45%
0 -0 0 0 0 2 2 3 4 7 4 2 3
Interest 1 0 0 0 0 0 1 1 1 0 0 0 0
Depreciation 1 1 1 1 1 1 1 2 2 3 4 5 8
Profit before tax 5 5 5 5 5 8 31 41 59 77 79 66 64
Tax % 0% 0% 0% 10% 20% 22% 24% 26% 26% 25% 25% 26%
5 5 5 4 4 6 24 30 44 58 59 49 48
EPS in Rs 0.42 0.42 0.42 0.40 0.36 0.59 2.17 2.77 4.00 5.32 5.43 4.48 4.43
Dividend Payout % 0% 0% 0% 0% 0% 0% 10% 0% 37% 14% 12% 15%
Compounded Sales Growth
10 Years: 17%
5 Years: 12%
3 Years: 10%
TTM: 1%
Compounded Profit Growth
10 Years: 26%
5 Years: 16%
3 Years: 4%
TTM: -8%
Stock Price CAGR
10 Years: 51%
5 Years: 64%
3 Years: 54%
1 Year: 43%
Return on Equity
10 Years: 39%
5 Years: 36%
3 Years: 32%
Last Year: 22%

Balance Sheet

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 7 7 7 7 7 7 7 7 7 7 7 11 11
Reserves -13 -8 -3 1 5 11 35 63 96 142 194 237 254
9 6 3 4 1 6 8 5 1 0 3 30 71
13 9 8 9 8 8 14 14 18 17 17 22 41
Total Liabilities 16 15 15 21 20 33 64 88 122 166 221 301 377
11 10 9 11 11 15 17 19 19 33 38 41 162
CWIP 0 0 0 0 0 1 0 2 13 21 91 184 132
Investments 0 0 0 0 0 0 0 0 0 0 0 0 0
5 5 5 11 10 17 47 67 90 113 92 76 82
Total Assets 16 15 15 21 20 33 64 88 122 166 221 301 377

Cash Flows

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
4 3 4 3 6 1 1 11 40 39 64 91
-0 -0 -1 -3 -1 -6 -3 -2 -30 -20 -55 -112
-3 -3 -3 -0 -4 5 2 -5 -14 -13 -9 26
Net Cash Flow 1 -1 -0 0 1 0 -0 3 -4 6 0 5

Ratios

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 15 28 24 71 26 52 87 59 80 44 58 76
Inventory Days 78 194 144 255 201 33 75
Days Payable 947 240 84 145 131 99 218
Cash Conversion Cycle 15 28 24 71 -844 52 41 119 189 114 -7 -67
Working Capital Days -152 -76 -70 -42 -43 -58 42 80 155 91 50 46
ROCE % 208% 121% 81% 55% 42% 45% 84% 67% 67% 61% 45% 27%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
75.00% 75.00% 75.00% 75.00% 70.87% 70.87% 70.87% 70.87% 70.87% 70.87% 70.87% 70.87%
0.01% 0.01% 0.01% 0.01% 0.86% 1.05% 1.44% 1.49% 1.42% 1.91% 2.51% 2.95%
0.03% 0.03% 0.03% 0.03% 0.04% 0.82% 1.18% 1.17% 1.17% 1.17% 1.17% 1.17%
24.96% 24.95% 24.95% 24.96% 28.23% 27.26% 26.52% 26.47% 26.55% 26.05% 25.44% 25.01%
No. of Shareholders 16,55016,80417,37319,84628,65529,57630,28031,27130,93430,67328,94528,319

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls